menu
    • menu
    [{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"HGF-1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"OvaStem","moa":"T Cell","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"HGF-1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"HGF-1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Amniotic Fluid Derived Stem Cells","moa":"HGF-1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"CELZ-201","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Creative Medical Technology","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Creative Medical Technology"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Insulin Producing Islet Cell Therapy","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Greenstone Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Greenstone Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Creative Medical Technology \/ Greenstone Biosciences"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Creative Medical Technology

    Menu

    Creative Medical Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Creative Medical Reports Opioid Reduction in StemSpine® Mid-Term Study

                            Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.

                            Product Name : AlloStem

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Creative Medical Reports One-Year Positive Results for AlloStem in T2D

                            Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with Type 2 Diabetes.

                            Product Name : AlloStem

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : CELZ-201

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Greenstone Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Creative Medical Expands iPSCelz Collaboration with Greenstone Biosciences

                            Details : The collaboration aims to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 05, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Greenstone Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CELZ-201-DDT Phase 1/2 Shows Positive Data in Chronic Back Pain

                            Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.

                            Product Name : AlloStem

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 30, 2025

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Creative Medical Advances FDA Cleared ADAPT Trial for CELZ-201 in Back Pain

                            Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.

                            Product Name : AlloStem

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 13, 2024

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Producing Islet Cell Therapy

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Creative Medical Technology Develops iPSCelz® to Produce Human Insulin

                            Details : iPSCelz is a human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin, it is being investigated in patients with diabetes.

                            Product Name : iPSCelz

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 24, 2024

                            Lead Product(s) : Insulin Producing Islet Cell Therapy

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of ...

                            Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.

                            Product Name : AlloStem

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Recipient : Syneos Health

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial...

                            Details : CELZ-201 is the First Novel Allogenic Cellular Therapy in the Dorsal Artery of the Pancreas. CELZ-201 leverages unique approach harnessing the power of PRDC to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, with...

                            Product Name : CELZ-201

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : CELZ-201

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Syneos Health

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Fluid Derived Stem Cells

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product

                            Details : ImmCelz™ has been demonstrated effective in animal models of autoimmunity and is currently the subject of a pending IND filed by the Company with the FDA for the treatment of stroke victims.

                            Product Name : ImmCelz

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 12, 2021

                            Lead Product(s) : Amniotic Fluid Derived Stem Cells

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic fluid derived stem cells

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz® IND for Stroke Treatment

                            Details : The Company's ImmCelz® product utilizes a patient's own blood cells that have been "reprogrammed" in the laboratory by culturing with established universal donor stem cells, followed by re-infusion into the patient.

                            Product Name : ImmCelz

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 14, 2021

                            Lead Product(s) : Amniotic fluid derived stem cells

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth